Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study of safety of Isophosphoramide Mustard (IPM) in the treatment of advanced sarcoma.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single Arm | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ZIO-201 | Drug | ZIO-201 given for 3 consecutive days to be repeated every 21 days for up to 6 months |
|
| Measure | Description | Time Frame |
|---|---|---|
| toxicities | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| pharmacokinetics | 6 months |
Not provided
Metastatic and /or unresectable disease state after previous standard chemotherapy
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jonathan Lewis, MD, PhD | ZIOPHARM Oncology, Inc | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Santa Monica | California | United States | ||||
Not provided
| ID | Term |
|---|---|
| C542790 | palifosfamide lysine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Ann Arbor |
| Michigan |
| United States |